CorWave

Executive Summary

CorWave is a clinical-stage French medical device company developing a novel Left Ventricular Assist Device (LVAD) for advanced heart failure. The company's core innovation is a pulsatile, membrane-based pump designed to mimic the natural blood flow of the human heart, potentially reducing complications associated with continuous-flow LVADs such as gastrointestinal bleeding and aortic insufficiency. Founded in 2012 and headquartered in Clichy, CorWave aims to expand LVAD therapy to a broader patient population by offering a more physiological and reliable solution. The device has the potential to improve patient outcomes and quality of life, addressing a significant unmet need in the treatment of end-stage heart failure. CorWave is currently in Phase 1 clinical development, with early feasibility studies demonstrating safety and performance. The company has attracted attention from investors and strategic partners due to its differentiated technology. While still privately held, CorWave is progressing toward pivotal trials and eventual commercialization. Key upcoming catalysts include the completion of the ongoing first-in-human study, securing additional financing to fund pivotal trials, and interactions with regulatory authorities. If successful, CorWave's LVAD could become a leading therapy in the mechanical circulatory support market, which is expected to grow substantially as heart failure prevalence increases.

Upcoming Catalysts (preview)

• Q3 2026Completion of First-in-Human Study75% success
• Q4 2026Series C Financing Round80% success
• Q2 2027FDA IDE Approval for Pivotal Trial60% success